Supernus Pharmaceuticals Ownership | Who Owns Supernus Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Supernus Pharmaceuticals Ownership Summary


Supernus Pharmaceuticals is owned by 56.25% institutional investors, 4.27% insiders, and 39.49% retail investors. Blackrock is the largest institutional shareholder, holding 18.90% of SUPN shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 6.04% of its assets in Supernus Pharmaceuticals shares.

SUPN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockSupernus Pharmaceuticals56.25%4.27%39.49%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustrySpecialty & Generic Drug Manufacturers Stocks20.82%11.62%67.56%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock10.39M18.90%$278.00M
Blackrock funding, inc. /de8.74M15.49%$434.17M
Vanguard group6.05M10.72%$300.61M
Armistice capital2.84M5.06%$135.53M
Dimensional fund advisors lp2.71M4.81%$134.80M
State street2.19M3.90%$104.54M
Point72 asset management1.76M3.14%$84.18M
Renaissance1.73M3.07%$86.11M
Geode capital management1.47M2.61%$73.21M
Loomis sayles & co l p1.45M2.57%$72.01M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Krensavage asset management363.48K7.40%$17.37M
Quantedge capital pte121.10K3.17%$5.79M
Ashford capital management563.72K3.00%$26.94M
Catalio capital management, lp287.09K2.54%$13.72M
Armistice capital2.84M2.01%$135.53M
Villanova investment management54.87K1.82%$2.62M
Third avenue management189.49K1.71%$9.42M
Rice hall james & associates476.08K1.24%$22.75M
Bruce82.11K1.22%$3.92M
S&t bank/pa88.92K1.19%$4.25M

Top Buyers

HolderShares% AssetsChange
Point72 asset management1.76M0.14%1.25M
Woodline partners lp1.26M0.28%490.83K
Morgan stanley1.08M0.00%324.15K
Catalio capital management, lp287.09K2.54%287.09K
Abrdn271.57K0.02%271.57K

Top Sellers

HolderShares% AssetsChange
Macquarie group---2.53M
Armistice capital2.84M2.01%-1.98M
Polar capital---1.00M
Rubric capital management lp---595.37K
Aristotle capital boston305.27K0.75%-503.12K

New Positions

HolderShares% AssetsChangeValue
Catalio capital management, lp287.09K2.54%287.09K$13.72M
Abrdn271.57K0.02%271.57K$13.50M
Quantedge capital pte121.10K3.17%121.10K$5.79M
Norges bank120.40K0.00%120.40K$5.98M
Phocas financial81.32K0.53%81.32K$4.04M

Sold Out

HolderChange
Claris advisors, llc / mo /-1.00
Global financial private client-3.00
Mendota financial group-5.00
Stephens consulting-10.00
Hexagon capital partners-10.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025199-36.01%31,720,915-45.01%560.53%101-32.67%55-52.99%
Sep 30, 2025175-38.60%28,258,627-50.30%500.49%77-51.88%65-18.75%
Jun 30, 2025290-59,380,9950.51%1050.95%16311.64%80-15.79%
Mar 31, 2025286-2.72%59,007,517-0.81%1050.91%144-1.37%93-2.11%
Dec 31, 2024137-49.63%29,073,367-51.31%520.45%69-48.51%37-58.89%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
iShares Core S&P Small-Cap ETF3.47M6.04%-182.38K
Delaware Small Cap Core I2.00M3.62%-12.37K
Macquarie Small Cap Core I1.94M3.46%-145.53K
Nomura Small Cap Core I1.76M3.05%-62.50K
Vanguard US Total Market Shares ETF1.68M3.00%1.91K
Vanguard Total Stock Mkt Idx Inv1.72M2.99%34.62K
iShares Russell 2000 ETF1.30M2.26%236.26K
Vanguard Small Cap Index1.23M2.15%-1.20K
Polar Capital Biotech S Inc1.00M1.79%-175.00K
Stephens SMID Select Growth983.31K1.71%45.17K

Recent Insider Transactions


DateNameRoleActivityValue
Feb 19, 2026Sensenig Bethany-Sell$167.04K
Feb 19, 2026Sensenig Bethany-Sell$61.23K
Dec 19, 2025Mottola Frank SVP, Chief Tech. Ops. OfficerSell$757.05K
Dec 19, 2025Mottola Frank SVP, Chief Tech. Ops. OfficerSell$251.10K
Dec 18, 2025Bhatt Padmanabh P. Sr. VP of IP, CSOSell$31.55K

Insider Transactions Trends


DateBuySell
2026 Q1-2
2025 Q4-9
2025 Q3-21
2025 Q2--
2025 Q1-3

SUPN Ownership FAQ


Who Owns Supernus Pharmaceuticals?

Supernus Pharmaceuticals shareholders are primarily institutional investors at 56.25%, followed by 4.27% insiders and 39.48% retail investors. The average institutional ownership in Supernus Pharmaceuticals's industry, Specialty & Generic Drug Manufacturers Stocks, is 20.82%, which Supernus Pharmaceuticals exceeds.

Who owns the most shares of Supernus Pharmaceuticals?

Supernus Pharmaceuticals’s largest shareholders are Blackrock (10.39M shares, 18.90%), Blackrock funding, inc. /de (8.74M shares, 15.49%), and Vanguard group (6.05M shares, 10.72%). Together, they hold 45.12% of Supernus Pharmaceuticals’s total shares outstanding.

Does Blackrock own Supernus Pharmaceuticals?

Yes, BlackRock owns 18.90% of Supernus Pharmaceuticals, totaling 10.39M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 278M$. In the last quarter, BlackRock increased its holdings by 30.28K shares, a 0.29% change.

Who is Supernus Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Krensavage asset management is Supernus Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 7.40% of its assets in 363.48K Supernus Pharmaceuticals shares, valued at 17.37M$.

Who is the top mutual fund holder of Supernus Pharmaceuticals shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Supernus Pharmaceuticals shares, with 6.04% of its total shares outstanding invested in 3.47M Supernus Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools